Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds



Wyeth’s Winning Ways: Big Pharma Bounces Back

Posted on: 20 Apr 07


After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry.
In the past few days we have seen Merck and Schering-Plough announce results ahead of expectations, and now Wyeth joins the club too, with Q1 revenues up by 11%, earnings per share up 12%, and its Pharmaceuticals, Consumer Healthcare and Animal Health segments all hitting double-digit net revenue growth. Commenting on the results, Robert Essner, Chairman and Chief Executive Officer said “Wyeth’s financial performance in the 2007 first quarter was again outstanding. On top of that, the Company added momentum to our new product pipeline by successfully completing a number of important clinical trials for Pristiq for vasomotor symptoms and depression, Viviant for osteoporosis, and Aprela for osteoporosis and vasomotor symptoms.” So he seemed pleased then, and analysts appear to share the sense of optimism. As reported on, Chris Shibutani, an analyst with J.P. Morgan Securities Inc., said in a note to clients ``Wyeth's diversified pharmaceutical portfolio provides a reassuring buffer to individual product risks, which weigh on so many peers. We expect that its several growth drivers will continue to perform.'' Of course, don't take this as our recommendation to go wild on Wyeth stock, and DYOR. Find out more via the links below.

Paul Hartigan

Last updated on: 27/08/2010 11:40:18

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.